Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis

Fcγ receptors as regulators of immune responses

Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947

A quantitative analysis of kinase inhibitor selectivity

Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D. Y., Hassell, A. M., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K. E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,125

Rational design of inhibitors that bind to inactive kinase conformations

Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,096

Roles of Fc receptors in autoimmunity

Takai, T. (2002) · Nature reviews. Immunology · doi:10.1038/nri856 · Cited by 627

Crystal Structure of Hck in Complex with a Src Family–Selective Tyrosine Kinase Inhibitor

Schindler, T. H., Sicheri, F., Pico, A. R., Gazit, A., Levitzki, A., & Kuriyan, J. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80357-3 · Cited by 433

Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis

Nell, V. P. K., Machold, K. P., Stamm, T. A., Eberl, G., Heinzl, H., Uffmann, M., Smolen, J. S., & Steiner, G. E. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.035691 · Cited by 354

Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals

Shinohara, M., Koga, T., Okamoto, K., Sakaguchi, S., Arai, K., Yasuda, H., Takai, T., Kodama, T., Morio, T., Geha, R. S., et al. (2008) · Cell · doi:10.1016/j.cell.2007.12.037 · Cited by 327

B‐lymphocyte contributions to human autoimmune disease

Yanaba, K., Bouaziz, J., Matsushita, T., MAGRO, C. M. J., Clair, E. W. S., & Tedder, T. F. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00646.x · Cited by 326

Therapeutic B cell depletion impairs adaptive and autoreactive CD4 + T cell activation in mice

Bouaziz, J., Yanaba, K., Venturi, G. M., Wang, Y., Tisch, R., Poe, J. C., & Tedder, T. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709205105 · Cited by 315

QSAR analysis of nicotinamidic compounds and design of potential Bruton’s tyrosine kinase (Btk) inhibitors

Santos‐Garcia, L., de Assis, L. C., Silva, D. R., Ramalho, T. C., & da Cunha, E. F. F. (2015) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2015.1070750 · Cited by 17

Design and pharmaceutical applications of proteolysis-targeting chimeric molecules

Liang, Y., Nandakumar, K. S., & Cheng, K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114211 · Cited by 16

Small-molecule inhibitors for autoimmune arthritis: Success, failure and the future

Ho, L., & Lai, J. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.031 · Cited by 17

Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors

Li, X., Shi, B., Teng, Y., Cheng, Y., Yang, H., Li, J., Wang, L., He, S., You, Q., & Xiang, H. (2019) · MedChemComm · doi:10.1039/c8md00413g · Cited by 17

Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3

Morell, A., Čermáková, L., Novotná, E., Laštovičková, L., Haddad, M., Haddad, A., Portillo, R., & Wsól, V. (2020) · Cancers · doi:10.3390/cancers12123731 · Cited by 17

Inhibition of BTK improved APAP-induced liver injury via suppressing proinflammatory macrophages activation by restoring mitochondrion function

Guo, H., Xie, M., Liu, W., Chen, S., Ye, B., Yao, J., Xiao, Z., Zhou, C., & Zheng, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109036 · Cited by 16

Kinase Crystal Miner: A Powerful Approach to Repurposing 3D Hinge Binding Fragments and Its Application to Finding Novel Bruton Tyrosine Kinase Inhibitors

Mukherjee, P., Bentzien, J., Bosanac, T., Wang, M., Burke, M. J., & Muegge, I. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00213 · Cited by 16

Strategies to Overcome Resistance Mutations of Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Liu, L., Shi, B., Wang, X., & Xiang, H. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0145 · Cited by 18

Ligand binding: evaluating the contribution of the water molecules network using the Fragment Molecular Orbital method

Lukač, I., Wyatt, P. G., Gilbert, I. H., & Zuccotto, F. (2021) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-021-00416-3 · Cited by 17

Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design

Sabat, M., Dougan, D. R., Knight, B., Lawson, J. D., Scorah, N., Smith, C. R., Taylor, E. R., Vu, P., Wyrick, C., Wang, H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01026 · Cited by 16

Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors

Yang, M., Jiang, H., Yang, Z., Liu, X., Sun, H., Hao, M., Hu, J., Chen, X., Jin, J., & Wang, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114611 · Cited by 16

The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity

Smith, C. W., Harbi, M. H., Garcia‐Quintanilla, L., Rookes, K., Brown, H. C., Poulter, N. S., Watson, S. P., Nicolson, P. L. R., & Thomas, M. R. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15899 · Cited by 16

Optimization of novel reversible Bruton’s tyrosine kinase inhibitors identified using Tethering-fragment-based screens

Hopkins, B. T., Bame, E., Bell, N., Bohnert, T., Bowden-Verhoek, J. K., Bui, M., Cancilla, M. T., Conlon, P. R., Cullen, P. F., Erlanson, D. A., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.05.021 · Cited by 16

Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure–activity relationship

Wang, L., Zhang, Z., Yu, D., Yang, L., Li, L., He, Y., & Shi, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106577 · Cited by 16

Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors

Kawahata, W., Asami, T., Irie, T., & Sawa, M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.11.037 · Cited by 15

BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies

Kim, H.-O. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01546-0 · Cited by 15

Identification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor

Malarz, K., Korzuch, J., Marforio, T. D., Balin, K., Calvaresi, M., Mrozek‐Wilczkiewicz, A., Musioł, R., & Serda, M. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s403058 · Cited by 14

Bruton's TK Inhibitors: Structural Insights and Evolution of Clinical Candidates

Xing, L., & Huang, A. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.24 · Cited by 14

Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors

Musumeci, F., Sanna, M., Greco, C., Giacchello, I., Fallacara, A. L., Amato, R., & Schenone, S. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1355908 · Cited by 14

Ibrutinib

Schwarzbich, M., & Witzens‐Harig, M. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_17 · Cited by 14

More than just B-cell inhibition

Ruderman, E., & Pope, R. M. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3439 · Cited by 14

Rheumatoid Arthritis Therapy Based on B Cells

Liang, Y., Zha, M., Liu, Q., Lai, Z., Li, L., Shao, Y., & Sun, J. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s527687 · Cited by 13

Aberrant B cell receptor signaling in circulating naïve and IgA+ memory B cells from newly-diagnosed autoantibody-positive rheumatoid arthritis patients

Neys, S. F. H., Heutz, J. W., van Hulst, J. A. C., Vink, M., Bergen, I. M., de Jong, P. H. P., Lubberts, E., Hendriks, R. W., & Corneth, O. B. J. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103168 · Cited by 13

Discovery of Novel Bruton’s Tyrosine Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approaches Based on SVM Model, Pharmacophore and Molecular Docking

Wan, H., Wang, Z., Li, L., Cheng, C., Ji, P., Liu, J., Zhang, H., Zou, J., & Yang, S. (2012) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2012.01415.x · Cited by 13

Novel 6-amino-1,3,5-triazine derivatives as potent BTK inhibitors: structure-activity relationship (SAR) analysis and preliminary mechanism investigation

Xiao, M., Zhu, M., Wu, S., Ma, L., Qi, L., Ha, S., Xiong, S., Chen, M., Chen, D., Luo, G., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106263 · Cited by 12

Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton’s tyrosine kinase (BTK) inhibitors

Xin, M., Zhao, X., Huang, W., Qiu, J. J., Wu, G., Wang, Y., Tang, F. S., & Xiang, H. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.08.039 · Cited by 12

Pancreatic Effects of a Bruton’s Tyrosine Kinase Small-molecule Inhibitor in Rats Are Strain-dependent

Bhaskaran, M., Cornwell, P. D., Sorden, S. D., Elwell, M. R., Russell, N. R., Pritt, M. L., & Vahle, J. L. (2018) · Toxicologic Pathology · doi:10.1177/0192623318770163 · Cited by 11

Bruton’s tyrosine kinase: A promising target for treating systemic lupus erythematosus

Ding, Q., Zhou, Y., Feng, Y., Sun, L., & Zhang, T. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113040 · Cited by 10

Small-molecule BTK inhibitors: From discovery to clinical application

Tian, G., Chen, Z., Wang, B., Chen, G., & Xie, L. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108242 · Cited by 10

Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK)

Fu, T., Zuo, Y., Zhong, Z., Chen, X., & Pan, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114051 · Cited by 10

Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK

Srivastava, A., Ko, S. S., Watterson, S. H., Pattoli, M. A., Skala, S., Cheng, L., Obermeier, M. T., Vickery, R., Discenza, L., D’Arienzo, C. J., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00335 · Cited by 10

Medicinal perspectives and structure-activity relationship studies of pyrimidine based Bruton’s tyrosine kinase inhibitors as potential anticancer agents

Jha, K. T., Shome, A., Chahat, Chawla, V., & Chawla, P. A. (2023) · Process Biochemistry · doi:10.1016/j.procbio.2023.07.018 · Cited by 9

Streamlining SuFEx Inhibitor Development: A Unified Approach Using Photolabile and Orthogonal Sulfinate Protecting Groups

Patel, T. I., Williams, M., Chi, Y., Laha, R., & Moschitto, M. J. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202505984 · Cited by 9

What Happens in Successful Optimizations? A Survey of 2018–2024 Literature

Leeson, P. D. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03171 · Cited by 12

The Effects of Bruton Tyrosine Kinase Inhibition on Chemotaxis and Superoxide Generation in Human Neutrophils

Broides, A., Hadad, N., Levy, J., & Lévy, R. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0046-z · Cited by 9

Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases

Guo, Y., Hu, N., Liu, Y., Zhang, W., Yu, D., Shi, G., Zhang, B., Yin, L., Wei, M., Yuan, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01938 · Cited by 8

Covalent Targeting Drug Mediated Specific Lanthanide Tagging Towards In Situ Bruton's Tyrosine Kinase Quantification Using ICP-MS

Yan, X. (2024) · Atomic Spectroscopy · doi:10.46770/as.2024.078 · Cited by 8

Design and Synthesis of Novel 3‐(2‐Aminopyridin‐3‐yl)‐1,2,4‐Triazolo[4,3‐b]Pyridazine Derivatives as a Reversible Bruton's Tyrosine Kinase Inhibitors

Park, C. H., Kim, D., Jung, H., Jeon, J. H., Achary, R., Lee, J., Kim, P., Jung, H., Hwang, J. Y., Ryu, D. H., et al. (2018) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.11485 · Cited by 8

Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors

Ma, B., Metrick, C. M., Gu, C., Hoemberger, M., Bajrami, B., Bame, E., Huang, J., Mingueneau, M., Murugan, P., Santoro, J. C., et al. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128549 · Cited by 8

Correction to: Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis

Chan, P., Yu, J., Chinn, L. W., Prohn, M., Huisman, J., Matzuka, B., Hanley, W. D., Tuckwell, K., & Quartino, A. L. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-2761-x · Cited by 8

Therapeutic potential and recent progression of BTK inhibitors against rheumatoid arthritis

Paliwal, S., Bawa, S., Shalmali, N., & Tonk, R. K. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14582 · Cited by 7

Effects of orelabrutinib, a BTK inhibitor, on antibody‐mediated platelet destruction in primary immune thrombocytopenia

Yu, T., Han, S., Wang, L., Wang, H., Ni, X., Wang, R., Li, G., Hou, Y., Peng, J., Yan, Z., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20045 · Cited by 7

Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives

Robak, E., & Robak, T. (2022) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pamed4ed.4.22.14 · Cited by 7

Quantitative structure–activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods

Xu, A., Zhang, Y., Ran, T., Liu, H., Lü, S., Xu, J., Xiong, X., Jiang, Y., Lu, T., & Chen, Y. (2015) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2015.1032346 · Cited by 7

A Small Molecule Inhibitor of Bruton’s Tyrosine Kinase Involved in B-Cell Signaling

Ratzon, E., Bloch, I., Nicola, M., Cohen, E., Ruimi, N., Dotan, N., Landau, M., & Gal, M. (2017) · ACS Omega · doi:10.1021/acsomega.7b00576 · Cited by 7

Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A

Delignat, S., Russick, J., Gangadharan, B., Rayes, J., Ing, M., Voorberg, J., Kaveri, S. V., & Lacroix‐Desmazes, S. (2018) · Haematologica · doi:10.3324/haematol.2018.200279 · Cited by 7

Pharmacophore modeling and virtual screening in search of novel Bruton’s tyrosine kinase inhibitors

Sharma, A. K., & Thelma, B. K. (2019) · Journal of Molecular Modeling · doi:10.1007/s00894-019-4047-y · Cited by 7

Comprehensive Characterization of Bruton’s Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures

Darragh, A. C., Hanna, A. M., Lipner, J., King, A. J., Servant, N. B., & Jahic, M. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00540 · Cited by 8

Two small-molecule inhibitors of Toxoplasma gondii proliferation in vitro

Hua, Q., Lin, X.-J., Xiang, S.-P., Jiang, L., Cai, J.-H., Sun, J., Tan, F., & Mou, Y.-N. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1145824 · Cited by 6

Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis

Thakkar, M., Bhuniya, D., Kaduskar, R. D., Mengawade, T., Naik, K., Salunkhe, V. T., Bhalerao, A., Kurhade, S., Mavinahalli, J., Jain, V., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.02.026 · Cited by 6

Discovery of Affinity‐Based Probes for Btk Occupancy Assays

Qiu, H., Caldwell, R. D., Liu‐Bujalski, L., Goutopoulos, A., Jones, R. C., Potnick, J. R., Sherer, B., Bender, A. T., Grenningloh, R., Xu, D., et al. (2018) · ChemMedChem · doi:10.1002/cmdc.201800714 · Cited by 6

Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton’s tyrosine kinase (BTK) inhibitors

Dou, D., Sha, W., Diao, Y., Su, R., Qiao, Y., Yu, Z., Zhao, Z., Li, H., Chen, Z., & Xu, Y. F. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105541 · Cited by 6

B-Cell Antigen Receptor Signaling in Chronic Lymphocytic Leukemia: Therapeutic Targets and Translational Opportunities

Hill, R. J., Lou, Y. C., & Tan, S. (2013) · International Reviews of Immunology · doi:10.3109/08830185.2013.818141 · Cited by 6

Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors

Qiu, H., Liu‐Bujalski, L., Caldwell, R. D., Follis, A. V., Gardberg, A. S., Goutopoulos, A., Grenningloh, R., Head, J. C., Johnson, T. L., Jones, C. C., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.09.018 · Cited by 6

TR-FRET binding assay targeting unactivated form of Bruton’s tyrosine kinase

Asami, T., Kawahata, W., & Sawa, M. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.001 · Cited by 6

Ligand-biased regulation of PtdIns(3,4,5)P3-dependent signal transduction in GPCR control of pituitary hormone release

Pemberton, J. G., & Chang, J. P. (2016) · Endocrinology · doi:10.1210/en.2016-1552 · Cited by 6

Modulating the Binding Kinetics of Bruton’s Tyrosine Kinase Inhibitors through Transition-State Effects

Bravo, E., Li, Y., Lin, D. Y.-W., Srinivasan, B., Barone, M., Li, S. X., DelloRusso, F., Rahiyanath, A. S., Corrionero, A., Alfonso, P., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07063 · Cited by 7

Getting the Most Value from Your Screens: Advances in Hardware, Software, and Methodologies to Enhance Surface Plasmon Resonance Based Fragment Screening and Hit-to-Lead Support

Giannetti, A. M., Gilbert, H., Huddler, D. P., Reiter, M., Strande, C., Pitts, K. E., & Bravo, B. J. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782620938-00019 · Cited by 5

Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors

Chen, H., Song, P., Diao, Y., Hao, Y., Dou, D., Wang, W., Fang, X., Wang, Y., Zhao, Z., Ding, J., et al. (2018) · MedChemComm · doi:10.1039/c8md00019k · Cited by 5

A regulatory SH2 domain-targeting protein binder effectively inhibits the activity of Bruton’s tyrosine kinase and its drug-resistant variants

Jeong, S., Sohn, Y., Choi, Y., Park, J., & Kim, H. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.006 · Cited by 5

Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA

Meng, A., Humeniuk, R., Jürgensmeier, J. M., Hsueh, C., Matzkies, F., Grant, E. P., Truong, H., Billin, A. N., Yu, H., Feng, J. Y., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2439 · Cited by 5

Visible-Light-Mediated Direct Amidation of Arenes and Heteroarenes with N-Aminopyridinium Salts

Li, Y., Xia, C., Hao, X., Jin, K., Zhang, R., & Duan, C. (2022) · Synlett · doi:10.1055/a-1867-7228 · Cited by 5

Bruton’s tyrosine kinase in chronic inflammation: from pathophysiology to therapy

Reedquist, K. A., Hartkamp, L. M., & Radstake, T. R. D. J. (2015) · International Journal of Interferon Cytokine and Mediator Research · doi:10.2147/ijicmr.s71779 · Cited by 5

Discovery and Development of Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853)

Crawford, J. J., & Zhang, H. (2019) · ACS symposium series · doi:10.1021/bk-2019-1332.ch009 · Cited by 5

Enhanced Bruton’s tyrosine kinase activity in the kidney of patients with IgA nephropathy

Wei, J., Wang, Y., Qi, X., & Wu, Y. (2021) · International Urology and Nephrology · doi:10.1007/s11255-020-02733-2 · Cited by 5

Bruton’s tyrosine kinase (BTK) inhibitors: an updated patent review (2019–2024)

Cui, Z.-X., Yao, S.-X., Zhang, Y.-X., Lu, H., Sun, L., & Shi, L. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2554638 · Cited by 4

A Case Series and Literature Review on Zanubrutinib Therapy for the Treatment of Relapsed/Refractory Immune Thrombocytopenia

Ding, B., Li, M., Liu, L., Song, X., Zhang, Y., Xia, A., Liu, J., & Zhou, H. (2025) · Cancer Reports · doi:10.1002/cnr2.70152 · Cited by 4

Bruton tyrosine kinase (Btk) suppresses osteoblastic differentiation

Kaneshiro, S., Ebina, K., Shi, K., Yoshida, K., Otsuki, D., Yoshikawa, H., & Higuchi, C. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0612-8 · Cited by 4

Phenotypic Approaches to Identify Inhibitors of B Cell Activation

Rex, E., Kim, S., Wiener, J., Rao, N. L., Milla, M. E., & DiSepio, D. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115585724 · Cited by 4

Identification of a New Inhibitor That Stabilizes Interleukin-2-Inducible T-Cell Kinase in Its Inactive Conformation

Hantani, R., Hanawa, S., Oie, S., Umetani, K., Sato, T., & Hantani, Y. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219857542 · Cited by 4

Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors

Naik, P. P. (2022) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2022.100156 · Cited by 4

Two-Track Virtual Screening Approach to Identify the Dual Inhibitors of Wild Type and C481S Mutant of Bruton’s Tyrosine Kinase

Kim, T., Kim, K., Park, I., Hong, S., & Park, H. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00623 · Cited by 4

Design, synthesis and biological evaluation of novel pyrazolo-pyrimidin-amines as potent and selective BTK inhibitors

Joshi, D., Bahekar, R. H., Soman, S. S., Jadav, P., Patel, D. N., Goswami, A., Pethani, J. P., Kumar, J., Patel, J., Sundar, R., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106238 · Cited by 4

‘Turn On/Off’ fluorescence probe for the screening of unactivated Bruton’s tyrosine kinase

Kawahata, W., Asami, T., Fujii, I., & Sawa, M. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.03.063 · Cited by 4

Pyrazolo[3,4‐d]pyrimidine derivatives as irreversible Bruton's tyrosine kinase inhibitors

Yeom, H., Achary, R., Choi, Y., Park, C. H., Lee, J., Lee, H. K., Kim, P., & Cho, S. Y. (2022) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12490 · Cited by 4

Novel Intra-cellular Targeting Agents in Rheumatic Disease

Cohen, S. B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00065-6 · Cited by 4

Literature Search and Review

Auld, D., Simeonov, A. M., Lea, W., & Thomas, C. J. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2010.0805.lr · Cited by 4

Inhibition of bruton’s tyrosine kinase directly alleviates pathogenic CD4+ T cell response via PPAR-γ signaling in autoimmune uveitis

Xiao, Z., Li, Z., Zhu, W., Chen, G., Luo, X., Mai, Z., Wang, M., Huang, H., Li, Z., Shi, Y., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03622-0 · Cited by 3

Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors

Zhang, Y. S., Fu, H., Kang, X., Qiu, Z., Yan, H., He, Q., Yang, B., Xu, Z., & Luo, P. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1726458 · Cited by 3

Involvement of Btk in Cardiovascular Disease and Its Therapeutic Targeting

von Hundelshausen, P., Siess, W., Duan, R., Bohnert, T., Hopkins, B. T., & Weber, C. (2026) · Circulation · doi:10.1161/circulationaha.125.076186 · Cited by 3

Effects of Quinidine or Rifampin Co‐administration on the Single‐Dose Pharmacokinetics and Safety of Rilzabrutinib (PRN1008) in Healthy Participants

Rask‐Madsen, C., Katragadda, S., Li, M., Ucpinar, S., Chinn, L. W., Arora, P. S., & Smith, P. F. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1404 · Cited by 3

Design, Synthesis, and Biological Evaluation of Pyrrolo[1,2-a]quinoxalin-4(5H)-one Derivatives as Potent and Orally Available Noncovalent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Tian, C., Du, H., Sha, W., Wu, L. E., Yu, Z., Song, H., Shen, Z., Dai, Y., Li, S., Mei, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00439 · Cited by 3

Streamlining SuFEx Inhibitor Development: A Unified Approach Using Photolabile and Orthogonal Sulfinate Protecting Groups

Patel, T. I., Williams, M., Chi, Y., Laha, R., & Moschitto, M. J. (2025) · Angewandte Chemie · doi:10.1002/ange.202505984 · Cited by 3

An Overview of Diverse Biological Activities of Cinnoline Scaffold

Asif, M., Almehmadi, M. M., Alsaiari, A. A., Aljuaid, A., Allahyani, M. A., & Alsharif, A. (2024) · Mini-Reviews in Organic Chemistry · doi:10.2174/0118756298265037231119063008 · Cited by 3

Small-Molecule Inhibitors of Bruton’s Tyrosine Kinase

Zuo, Y., & Pan, Z. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_6 · Cited by 3

Correction to “Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design”

Sabat, M. P., Dougan, D. R., Ermolieff, J., Halkowycz, P., Knight, B., Lawson, J. D., Scorah, N., Smith, C. R., Taylor, E. R., Vu, P. H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01685 · Cited by 3

B Cell Signaling and Activation in Autoimmunity

Hendriks, R. W., & Corneth, O. B. J. (2023) · Cells · doi:10.3390/cells12030499 · Cited by 3

Bruton’s Tyrosine Kinase Inhibitors: A Versatile Therapeutic Approach for Cancer, Autoimmune Disorders, GVHD and COVID-19

Paliwal, S., Agarwal, U., & Tonk, R. K. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575409452250815095743 · Cited by 2

Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis

Lambe, J., & Fox, R. J. (2026) · Drugs · doi:10.1007/s40265-026-02324-y · Cited by 2

Synergistic effect of Bruton's tyrosine kinase and TNF‑α in the regulation of rheumatoid arthritis and underlying mechanisms

Du, J. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.11064 · Cited by 2

Research Progress of BTK Inhibitors in the Treatment of Inflammatory and Autoimmune Diseases

杨, 婉. (2022) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2022.101008 · Cited by 2

Inhibition of proteolytic and ATPase activities of the proteasome by the BTK inhibitor CGI-1746

Akintola, O. A., Patterson, M. B., Smith, J. G., Demartino, G., Mitra, A., & Kisselev, A. F. (2024) · iScience · doi:10.1016/j.isci.2024.110961 · Cited by 2

Bruton tyrosine kinase promotes wound healing after myocardial infarction by inhibiting the transcription of u-PA

Dong, Z., Zhu, J., Cheng, S., Weng, X., Sun, X., Qian, J., Zou, Y., Sun, A., Wang, S.-J., Ma, L.-L., et al. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.12.008 · Cited by 2

Sequelae of B-Cell Depleting Therapy: An Immunologist’s Perspective

Kačar, M., Al‐Hakim, A., & Savic, S. (2024) · BioDrugs · doi:10.1007/s40259-024-00696-9 · Cited by 2

Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory Activity

Qiu, H., Ali, Z., Bowlan, J., Caldwell, R. D., Gardberg, A. S., Glaser, N., Goutopoulos, A., Head, J. C., Johnson, T. L., Maurer, C. K., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100453 · Cited by 2

Bruton's Tyrosine Kinase (Btk)

Schnute, M. E., Huang, A. J., & Saiah, E. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735346-00297 · Cited by 2

Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant

Libre, C., Moro-Sibilot, L., Giraud, S., Martin, L., Verhoeyen, E., Costa, C., Chebel, A., Bissay, N., Salles, G., Genestier, L., et al. (2020) · Cancers · doi:10.3390/cancers12040901 · Cited by 2

Multiwalled Carbon Nanotubes as Nanomaterial Tool in the Management of Prostate Cancer: A Possible Nanoformulation Approach

Murugesan, R., Sureshkumar, R., Radhakrishnan, A., Jupudi, S., & Manisha, C. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.053 · Cited by 2

4-Aminopyrazolopyrimidine scaffold and its deformation in the design of tyrosine and serine/threonine kinase inhibitors in medicinal chemistry

Chen, X., Huang, Y., Xu, W., Cai, Y., & Yang, Y. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00139j · Cited by 2

Dual Targeting of Janus Kinase and Bruton’s Tyrosine Kinase: A New Approach to Control the Pathogenesis of Rheumatoid Arthritis

Pery, N., Ijaz, F., Rizvi, N. B., Munawar, M. A., & Shafiq, M. I. (2020) · Pakistan Journal of Zoology · doi:10.17582/journal.pjz/20191010081058 · Cited by 2

HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis

Park, J. K., Byun, J., Park, J. A., Kim, Y.-Y., Lee, Y. J., Oh, J. I., Jang, S. Y., Kim, Y., Song, Y. W., Son, J., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0988-z · Cited by 68

Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

Whang, J. A., & Chang, B. Y. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.028 · Cited by 95

A novel Highly Specific Small Molecule Inhibitor for BTK Suppresses Fc Receptor Function in Macrophages and Prevents Inflammatory Arthritis (96.18)

Reif, K., Huang, T., Barbosa, J., Hymowitz, S. G., Gallion, S. L., Hurez, V. J., Maciejewski, P. M., Dennis, G., Rong, H., Shen, F., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.184.supp.96.18

Therapeutic potential and recent progression of BTK inhibitors against rheumatoid arthritis

Paliwal, S., Bawa, S., Shalmali, N., & Tonk, R. K. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14582 · Cited by 7

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model

Wu, H., Huang, Q., Qi, Z., Chen, Y., Wang, A., Chen, C., Liang, Q., Wang, J., Chen, W., Dong, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00482-4 · Cited by 23